anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chromosomal instability (CIN), defined by variations in the number or structure of chromosomes from cell to cell, is recognized as a distinctive characteristic of cancer associated with the ability of tumors to adapt to challenging environments. CIN has been recognized as a source of genetic variation that leads to clonal heterogeneity (CH). Recent findings suggest a potential association between CIN and CH with the prognosis of BC patients, particularly in tumors expressing the epidermal growth factor receptor 2 (HER2+). In fact, information on the role of CIN in other BC subtypes, including luminal B BC, is limited. Additionally, it remains unknown whether CIN in luminal B BC tumors, above a specific threshold, could have a detrimental effect on the growth of human tumors or whether low or intermediate CIN levels could be linked to a more favorable BC patient prognosis when contrasted with elevated levels. Clarifying these relationships could have a substantial impact on risk stratification and the development of future therapeutic strategies aimed at targeting CIN in BC. This study aimed to assess CIN and CH in tumor tissue samples from ten patients with luminal B BC and compare them with established clinicopathological parameters. The results of this study reveal that luminal B BC patients exhibit intermediate CIN and stable aneuploidy, both of which correlate with lymphovascular invasion. Our results also provide valuable preliminary data that could contribute to the understanding of the implications of CIN and CH in risk stratification and the development of future therapeutic strategies in BC.
Aspects of the technology include methods and systems for performing remote adjustments to a ventilator with a remote device. A remote device may include an interactive display including a remote position indicator. The remote position indicator may be associated or correlated with a local ventilator position indicator. A selection and/or adjustment at the remote device (or an activation at the remote device) at the interactive display may result in a selection, adjustment, or activation at the ventilator. Information may be transmitted to the ventilator from the remote device to remotely adjust the ventilator. Additionally or alternatively, the remote device may additionally display a view of, or replicate, some or all portions of the ventilator display.
Kidney transplant can help patients with end-stage kidney disease to get rid of dialysis and have a good quality life. However, during the renal donation operation, the stress response and subsequent inflammatory responses may result in damage to the residual kidney and transplanted kidney. In addition, the transplanted kidney will encounter ischemic and reperfusion injuries during kidney transplant, and it may affect its function. It has been reported in several animal studies that dexmedetomidine can reduce microcirculatory dysfunction, kidney injury, and intestinal injury. Moreover, dexmedetomidine can increase urine output and decrease the neutrophil gelatinase associated lipocalin level in patients receiving coronary artery bypass surgery. The primary goal of this trial is to investigate the effects of perioperative infusion of dexmedetomidine on the microcirculation and residual kidney function in kidney donors and on the transplanted kidney function in kidney recipients. This is a single blind and randomized controlled trial. The participants will be randomly assigned to the Control group or Dexmedetomidine group. The participants in the Control group will receive standard anesthesia care for kidney donation operation. Beside the standard anesthesia care, the participants in the Dexmedetomidine group will receive continuously intravascular infusion of dexmedetomidine since 10 minutes after anesthesia till one hour after operation. At several specific time points, participants will receive sublingual microcirculation examination by using an incident dark field video microscope and blood tests. The chart information will be recorded. The blood creatinine level of the kidney donors and recipients at 1 and 6 months will be recorded.
The present invention relates to a double-stapled novel peptide. More specifically, the present invention relates to a double-stapled peptide, and an antibacterial or anticancer composition including the same. The double-stapled peptide according to the present invention has a doubly introduced staple, so the peptide can be effectively stabilized in a spiral secondary structure. Moreover, a proteinase cannot recognize a spiral peptide as a substrate, so a peptide having a secondary structure stabilized in a spiral shape by means of a staple can have high stability with respect to the proteinase. Moreover, amino acid having a positive charge is disposed in the opposite position of the staple, which is hydrophobic in a spiral structure obtained through stapling, so a bipolar spiral structure is formed. Like many antibacterial peptides existing in nature, an antibacterial action can be shown by the cell membrane destruction of bacteria. Accordingly, the double-stapled peptide according to the present invention can be used for various purposes requiring antibacterial activities, and is expected to be able to be useful as an anticancer composition.
NEW MATERIAL:A vascular endothelial cell growth factor protein having the following properties. Molecular weight under nonreducing condition; 38,000-48,000. Inactivated by reduction treatment. Isoelectric point.; 8.5-9.0. USE:A curing promoter for burns or wounds, remedy for cardiovascular disorder, remedy and diagnostic agent for malignant tumor, retinopathy, chronic rheumatism, etc. PREPARATION:For example, human diploid fibroblasts are cultivated and propagated in a culture medium and the resultant cultivation supernatant is then adjusted to pH 4.5 and passed through a heparin.Sepharose(R) column to adsorb components, which are subsequently eluted and subjected to column treatment and reversed phase column chromatography. The adsorbed components are then eluted and purified at 0-70% acetonitrile concentration gradient in the presence of 0.1% trifluoroacetic acid to afford the aimed vascular endothelial cell growth factor (ECGF).
* Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1), Drug Interactions (7.1)]. 
  * The use of benzodiazepines, including alprazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)]. 
  * The continued use of benzodiazepines, including alprazolam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].
BACKGROUND: Malignant cells exhibit reduced period circadian regulator 3 (PER3) expression. However, the underlying mechanisms of variations in PER3 expression in cancers and the specific function of PER3 in tumor progression remain poorly understood.
RESULTS: We explored multiple public databases, conducted bioinformatics analyses, and performed in vitro and in vivo experiments for validation. We found PER3 expression was decreased in most types of cancers, and PER3 downregulation was associated with a poor prognosis in 8 types of cancer. PER3 promoter methylation levels were increased in 11 types of cancer. Promoter hypermethylation (CpG islands [CGIs] cg12258811 and cg14204433) correlated with decreased PER3 expression in six cancers (breast invasive carcinoma, colon adenocarcinoma, head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma [KIRP], lung adenocarcinoma [LUAD], and uterine corpus endometrial carcinoma). CGI cg12258811 hypermethylation was associated with reduced survival time and advanced cancer stages. Moreover, the bisulfite pyrosequencing assay confirmed CGI cg12258811 hypermethylation and its negative correlation with PER3 expression. In vitro and in vivo experiments demonstrated that PER3 inhibited KIRP and LUAD progression. Decitabine enhanced PER3 expression and inhibited KIRP cell functions by reducing promoter (cg12258811) methylation level.
CONCLUSIONS: Our findings advanced the mechanistic understanding of variations in PER3 expression in cancers and confirmed the tumor-associated function of PER3 hypermethylation and downregulation.
Subjects who meet the selection criteria will be offered an opportunity to take part in this study. This will be a prospective controlled study. After written informed consent, 20 subjects with symmetric thick plaque psoriasis lesions on the extremities and/or trunk will be enrolled and randomized to receive one activated iontophoresis patch containing dexamethasone sodium phosphate and another inactive control iontophoresis patch containing dexamethasone sodium phosphate on each limb containing a thick psoriatic plaque. Members of the research team will apply the patches. After application of the patch, subjects will be asked to return to the clinic in 1 week and 2 weeks. Efficacy will be measured at the 1-week and 2-week follow-up visit using a scale for erythema, scale, and thickness called the static Physician Global Assessment (sPGA) and subject satisfaction to treatment will be measured at the 2 week-follow-up using the PsoSat Questionnaire.
OBJECTIVE: While sleeve gastrectomy (SG) results in sustained weight loss for the majority of patients, some will experience inadequate weight loss or weight regain requiring revision. The objective of this study was to evaluate differences in weight loss over time between patients undergoing Roux-en-Y gastric bypass (RYGB) or single anastomosis duodenoileostomy (SADI) after SG.
METHODS: We queried a single institution's bariatrics registry to identify patients who underwent RYGB or SADI after previous SG over a three-year period. Demographics, operative characteristics, and post-operative complications were evaluated. Interval total body weight loss (TBWL) and excess body weight loss (EBWL) were calculated from available follow-ups within 2 years.
RESULTS: We identified 124 patients who underwent conversion to RYGB (n = 61) or SADI (n = 63) following previous SG. There were no differences in sex, age, or medical comorbidities between groups. The median initial BMI was higher in the SADI group (44.9 vs. 41.9 for RYGB, p = 0.03) with greater excess body weight (56.7 vs. 64.3 kg, p = 0.04). The SADI group had a shorter median operative duration (157 vs. 182 min for RYGB, p < 0.01) and lower readmission rates (0 vs. 14.75%, p < 0.01). There was no difference in post-operative complications or need for rehydration therapy between the groups. Among 122 patients (98.4%) that had follow-up weights available, there were no differences in TBWL between groups. RYGB patients had a higher EBWL at 2, 3, and 6 months (p < 0.05 for all comparisons), but there were no differences between RYGB and SADI at 1 or 2 years.
CONCLUSIONS: Both RYGB and SADI conversions proved effective for further weight loss following failed SG at our academic center. While neither demonstrated clear superiority in long-term (> 1 year) weight loss, RYGB's restrictive gastric pouch may explain its early weight loss advantage.
PURPOSE:To provide an aqueous gel cosmetic absolutely free from irritation, and having excellent application feeling and spreadability, by adding a water- soluble inorganic salt or a neutral organic salt to an aqueous solution of an alkali metal solt of deoxyribouncleic acid, and gelatinizing the solution. CONSTITUTION:An aqueous solution of an alkali metal salt (usually Na salt or K salt) of deoxyribonucleic acid having a concentration of 1-10% (preferably 3-6%) is gelatinized with 0.1-10% (preferably 0.5-5%) electrolyte such as water-soluble inorganic salt or neutral organic salt, etc. (e.g. NaCl, sodium lactate, etc.) to obtain an aqueous gel cosmetic. The gel cosmetic base is transparent and has arbitrarily adjustable hardness. A composition obtained by mixing the base with other water-soluble or water-dispersible additives and various conventional preservative, pH-modifier, perfume, dye, etc. for cosmetic exhibits extremely stable gel structure at 4-8pH which is a pH range of conventional cosmetics.
The present invention relates to a composition for preventing, relieving, or treating dental caries and periodontal disease. The composition according to the present invention has characteristics capable of offering improving effects on sugar control of a diabetic as well as preventing, relieving, or treating dental caries and periodontal disease. The present invention relates to a composition for preventing, relieving, or treating dental caries and periodontal disease, which contains cryptotanshinone as an active ingredient. Especially, cryptotanshinone has efficacy corresponding to 0.5-32 ug/ml of minimal inhibitory concentration (MIC) and 1-64 ug/ml of minimal bactericidal concentration (MBC) with respect to pathogenic organisms of dental caries and periodontal disease. The present invention relates to a composition for preventing, relieving, or treating dental caries and periodontal disease, which contains a mixture of cryptotanshinone and red ginseng extract or an existing antibacterial substance as an active ingredient. The composition has efficacy causing synergistic effects especially by containing the mixture of cryptotanshinone and the red ginseng extract or existing antibacterial substance as the active ingredient. In addition, the growth of the pathogenic organisms of dental caries and periodontal disease completely perishes in 3 to 5 hours after a mixture of 1/2 MIC of cryptotanshinone and the red ginseng extract or existing antibacterial substance is applied. The present invention relates to health functional food for preventing or relieving dental caries and periodontal disease, which contains cryptotanshinone or cryptotanshinone and the red ginseng extract as active ingredients.
PURPOSE:To provide a toothpaste composition having increased commercial value by its refreshing feeling and characteristic deliciousness, by using a paste of particles having specific diameter and obtained by grinding peppermint leaves together with water or an aqueous solution of sugars or polyhydric alcohols. CONSTITUTION:Peppermint leaves are ground together with water or an aqueous solution of sugars (e.g. inverted sugar liquid, sucrose, sorbitol, etc.) or polyhydric alcohols (e.g. glycerine, propylene glycol, etc.) to obtain a paste having particle size of 1-50mu. The paste is used as a component of a toothpaste composition. The dissipation of the active component in air is inhibited by the grinding of the peppermint leaves in the presence of water, and the nonvolatile components are also retained in the resultant paste. Consequently, the toothpaste composition containing said paste has agreeable taste as well as refreshing feeling. The amount of the paste in the toothpaste composition is preferably 0.05-0.2wt%.
FIELD: medicine, stomatology. SUBSTANCE: the present innovation deals with manufacturing dental pastes. The suggested dental paste contains chalk, sodiumcarboxymethylcellulose, either glycerol or sorbitol, sodiumlaurylsulfate, lavender bioconcentrate, castor oil, mint oil, conservant and water. These components should be taken at certain quantitative ratio. The suggested dental paste provides curative and prophylactic action upon organs and tissues of mouth cavity, has got pleasant taste and odor. EFFECT: higher quality of dental paste. 6 cl, 2 ex
Hip resurfacing arthroplasty (HRA) has been advocated as an attractive therapy for a younger, more demanding patient population with debilitating hip osteoarthritis. Controversies surrounding metal-on-metal (MoM) hip resurfacing have, however, led to a significant decline in the popularity of the HRA. Despite this, substantial evidence supports the use of specific implants in a selected group of patients. This is a continued retrospective analysis of a single surgeon series of the Birmingham Hip Resurfacing (BHR). Initial medium-term analysis was done in 2011 and published by Van der Bracht et al.13. This analysis includes a long-term follow-up of 7 to 12 years, including functional scoring (HHS, HOOS and UCLA activity score), metal ion evaluation and survival analysis. Failure was defined as revision for any cause. A total of 267 resurfacing procedures with the BHR were included in 247 patients. We had a mean follow-up of 8.3 years. Overall survival at ten years was 94.8%(97.2% for males and 90.1% for females). There was a statistically significant increase in mean HHS score at follow-up (56.03 - IQR 47-65 to 96.07 - IQR 96-100). Elevated metal ions were correlated with a statistically significant increase in the probability of complications. This cohort study further proved that hip resurfacing arthroplasty with the Birmingham Hip Resurfacing implant provides a good alternative to conventional total hip arthroplasty in young patients. There was a significant increase in functional scores at follow-up. There is further evidence of less favorable outcomes in female patients.
BACKGROUND: Extracellular vesicles (EVs) modulate inflammation, coagulation and vascular homeostasis in decompensated cirrhosis.
AIM: To characterize the profile of plasmatic EVs in patients with decompensated cirrhosis and bacterial infections and evaluate the association between EVs and the development of hemostatic complications.
METHODS: We measured the levels of EVs using high-sensitivity flow cytometry and phospholipid-dependent clotting time (PPL) in a prospective cohort of hospitalized patients with acutely decompensated cirrhosis with versus without bacterial infections. A separate cohort of patients with bacterial infections without cirrhosis was also enrolled. We measured endothelium-, tissue factor (TF)-bearing, platelet- and leukocyte-derived EVs. In patients with infections, EVs were reassessed upon resolution of infection. Bleeding and thrombotic complications were recorded during 1-year follow-up.
RESULTS: Eighty patients with decompensated cirrhosis were recruited (40 each with and without bacterial infections). Electron microscopy confirmed the presence of plasma EVs. Despite no difference in total EVs and PPL, patients with cirrhosis and infection had significantly higher TF+ EVs, P-Selectin+ EVs (activated platelet-derived), CD14+ EVs (monocyte/macrophages derived) and CD14+ TF+ EVs versus those with cirrhosis without infection. Upon infection resolution, levels of these EVs returned to those without infection. Patients with infections showed a significant association between reduced P-Selectin+ EVs and bleeding complications (HR 8.0 [95%CI 1.3-48.1]), whereas high levels of leukocyte-derived EVs (CD45+) and CD14+ EVs were significantly associated with thrombotic complications (HR 16.4 [95%CI 1.7-160] and 10.9 [95%CI 1.13-106], respectively). Results were confirmed in a validation cohort.
CONCLUSION: Bacterial infections are associated with particular alterations of plasma EVs profile in decompensated cirrhosis. Bacterial infections trigger the release of EVs originating from various cell types, which may tip the precarious hemostatic balance of patients with acutely decompensated cirrhosis towards hyper- or hypocoagulability.
Systems and methods are provided for providing mental health intervention using a virtual environment. A spoken communication from a first user is conveyed to a second user in a virtual environment. Data about the first user is collected as the first user interacts with the second user. The collected data includes tone information from the spoken communication. A clinical parameter representing a mental state of the first user is determined from the collected data at a machine learning model. A prompt is provided to the second user, representing one of a suggested phrase, a suggested sentence, and a suggested topic of conversation, according to the determined clinical parameter.
Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
The invention concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine- Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3α exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3α-transgenic mice resist better to DSS-induced colitis after antibiotherapy. Thus, the invention concerns a Reg3α polypeptide for use in the protection of oxygen sensitive gram-positive bacteria, notably the Ruminococcaceae, such as Faecalibacterium prausnitzii, and/or the Lachnospiraceae, such as Roseburia intestinalis; pharmaceutical compositions comprising the polypeptide and their use; and the use of this polypeptide for promoting ex vivo growth of oxygen sensitive gram-positive bacteria. The Reg3α polypeptide may be used for preventing or treating microbiota-related disease and/or disorder, particularly selected from inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.
The present invention relates to an antibody that binds to human lymphocyte activation gene 3(LAG-3) and uses thereof. In particular, the antibody or antigen-binding fragment thereof comprises: (a) heavy chain CDR1 comprising SEQ ID NO. 5, heavy chain CDR2 comprising SEQ ID NO. 6, and heavy chain CDR3 comprising SEQ ID NO. 7; and (b) a light chain CDR1 comprising SEQ ID NO 8, a light chain CDR2 comprising SEQ ID NO 9, and a light chain CDR3 comprising SEQ ID NO 10. The antibody disclosed by the invention can specifically recognize LAG-3 protein, can effectively block the combination of MHCII or FGL1 and LAG-3 molecules, and has potential tumor inhibition activity.